ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Patent Strategies for Generic Medicines and Generic Medicine Companies - 1 Day Virtual Training Course, October 21, 2025 - ResearchAndMarkets.com

The "Patent Strategies for Generic Medicines and Generic Medicine Companies Training Course (Oct 21, 2025)" has been added to ResearchAndMarkets.com's offering.

In the highly competitive pharmaceutical industry, patent strategies for generic medicines are crucial for success. To successfully bring a generic medicine to market, it is necessary to navigate a complex patent landscape in order to avoid infringing existing patents.

Attending this course will give you a thorough understanding of IP strategies specifically tailored for generic medicines, equipping you with the tools to navigate the complex landscape of pharmaceutical patents and SPCs.

The course will cover how to conduct a robust Freedom to Operate (FTO) analysis to identify and analyse potential patent infringement issues. Drawing on the shared experience of the expert trainers, you will learn to navigate the patent landscape and identify the risks for generic products entering the market.

Acquiring insights into identifying and managing blocking patents, with a focus on when and where to take action, you will understand whether to pursue oppositions or litigation.

It's crucial to stay updated with the most recent EPO case law, particularly on inventive step as this is the area that has proven to be most successful when challenging patent validity. This will enable you to craft strong arguments for challenging a patent and improve your patent strategy.

Understanding the legal framework surrounding Supplementary Protection Certificates (SPCs) in the EU and UK, will ensure you are fully aware of the specific requirements for these separate IP rights when compared to the patents they are based on. Options for challenging the validity of SPCs based on most recent case law will be explored.

The expert trainers for this course will use case studies and real-world examples to help embed the learning and enhance your practical knowledge. You will leave the course with the understanding and skills to be able to apply these strategies effectively within your own context.

Key topics covered in this course include:

  • Comprehensive IP knowledge for generic medicines
  • Freedom to operate (FTO)
  • Strategic management of blocking patents
  • Latest legal insights
  • SPC legal landscape
  • Practical applications

Benefits of attending

By attending this course, you will:

  • Get to grips with the process of Freedom to Operate (FTO) analysis, including assessing potential patent infringement risks and understanding issues around data exclusivity
  • Develop the ability to identify and manage blocking patents
  • Evaluate whether to pursue oppositions at the EPO or seek revocation of a patent at the new Unified Patent Court (UPC)
  • Gain up-to-date knowledge on EPO case law concerning inventive step, and on emerging UPC case law, and how such arguments can be used to challenge the validity of patents
  • Understand the legal intricacies and case law of Supplementary Protection Certificates (SPCs), including strategies to challenge their validity
  • Learn how to implement these IP strategies in the context of generic medicines, ensuring such products can effectively compete in the pharmaceutical market

Certifications:

  • CPD: 6 hours for your records
  • Certificate of completion

Who Should Attend:

This course has been specially designed for professionals in generic medicines, including:

  • In-house IP and patent lawyers and legal advisers
  • Private practice patent lawyers
  • IP managers/professionals
  • Senior patent administrators and paralegals
  • Other professionals responsible for managing a patent portfolio

Course Agenda:

Freedom to operate

  • What is 'Freedom to operate' analysis?
  • Data exclusivity
  • Assessing patent infringement
  • Watch out for potential specific patent issues around the following:
    • Stereochemistry
    • Polymorphs
    • New formulations
    • Process patents
    • Methods of use patents

Problem patents - assessing and managing blocking patents

  • Oppositions at the European Patent Office (EPO)
  • Litigation at the Unified Patent Court (UPC)
  • Oppositions versus litigation - factors in deciding on strategy
  • Where to take action? When to take action?
  • Successful strategies from case law

The latest updates from UPC and EPO case law: Inventive step

  • EPO problem-solution approach to assessing inventive step
  • Developing arguments for lack of inventive step
  • Impact of emerging UPC case law

Supplementary Protection Certificates (SPCs)

  • The EU legal framework
  • The UK legal framework

Exploring the validity of SPCs - lessons from the case law

  • Questions that arise under Article 3?
  • Same or different - EU and UK?

Other aspects arising from SPCs

  • Paediatric extensions
  • Manufacturing waiver
  • Regulatory exclusivities

For more information about this training visit https://www.researchandmarkets.com/r/dckok2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.28
+1.87 (0.77%)
AAPL  269.54
+1.07 (0.40%)
AMD  244.49
+10.95 (4.69%)
BAC  53.48
+0.28 (0.53%)
GOOG  286.79
+7.09 (2.53%)
META  628.39
+6.68 (1.08%)
MSFT  502.36
+5.54 (1.12%)
NVDA  194.77
+6.62 (3.52%)
ORCL  242.06
+2.80 (1.17%)
TSLA  448.42
+18.90 (4.40%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.